Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioventus Inc Cl A (NQ: BVS )

4.000 +0.030 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 116,772
Open 3.980
Bid (Size) 4.000 (7)
Ask (Size) 4.020 (3)
Prev. Close 3.970
Today's Range 3.952 - 4.050
52wk Range 0.9499 - 6.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
From Bioventus, Inc.
Via GlobeNewswire
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLND) rose sharply during Friday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-23.81%
-23.81%
1 Month
-20.95%
-20.95%
3 Month
-10.71%
-10.71%
6 Month
+11.27%
+11.27%
1 Year
+321.01%
+321.01%

More News

Read More
Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
A Preview Of Bioventus's Earnings
Via Benzinga
Earnings Preview: Bioventus
Via Benzinga
Bioventus Earnings Preview
Via Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
From Bioventus, Inc.
Via GlobeNewswire
Earnings Scheduled For March 12, 2024
Via Benzinga
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
From Bioventus, Inc.
Via GlobeNewswire
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bioventus Names Robert Claypoole as President and Chief Executive Officer
From Bioventus, Inc.
Via GlobeNewswire
MedTech Bioventus' Stabilization Sparks Analyst Confidence, Earns Upgrade And Price Target Boost
Via Benzinga
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
From Bioventus, Inc.
Via GlobeNewswire
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Cantor Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
Bioventus And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.